This site is intended for healthcare professionals

Keytruda + Lenvima demonstrated statistically significant improvement in progression-free survival , overall survival and objective response rate versus sunitinib as first-line treatment for renal cell carcinoma.- Merck Inc. + Eisai

Read time: 1 mins
Last updated:12th Nov 2020
Published:12th Nov 2020
Condition: Renal Cell Carcinoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest